文献速递肺外科

可切除非小细胞肺癌新辅助纳武利尤单抗后肺切除的初步结果

Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer.
PubMed 文献 · J Thorac Cardiovasc Surg · 2018-12-13

一项I期试验评估可切除非小细胞肺癌患者接受2周期新辅助纳武利尤单抗(3 mg/kg)后肺切除的安全性。22例入组,20例手术,无手术死亡,50%出现并发症,最常见为房性心律失常(30%),45%达主要病理缓解;胸腔镜/机器人手术中54%中转开胸。

要点

  • 新辅助纳武利尤单抗未增加意外围术期并发症或死亡。
  • 主要病理缓解率达45%(9/20)。
  • 胸腔镜/机器人手术中54%因肺门炎症纤维化中转开胸。

核心结论

  • 可切除NSCLC患者接受新辅助纳武利尤单抗后肺切除未出现意外的围术期并发症或死亡。

研究设计与样本

  • I期试验,纳入未治疗I-IIIA期NSCLC患者,术前4周和2周接受2周期纳武利尤单抗3 mg/kg,主要终点为安全性和可行性。

主要发现

  • 22例入组中20例接受切除,无手术死亡,10/20(50%)出现并发症。
  • 最常见术后并发症为房性心律失常(6/20,30%)。
  • 主要病理缓解见于9/20(45%)患者。
  • 胸腔镜或机器人入路尝试13例中7例(54%)中转开胸,常因肺门炎症和纤维化。

关键数值与推荐

  • 从首次治疗至手术中位时间33天(范围17-43天)。
  • 中位手术时间228分钟(范围132-312分钟),估计失血量100 mL(范围25-1000 mL),住院时间4天(范围2-17天)。
  • 手术方式:15例肺叶切除,2例全肺切除,1例双肺叶切除,1例袖式肺叶切除,1例楔形切除。

临床怎么用

  • 新辅助纳武利尤单抗后肺切除可行,但需警惕房性心律失常。
  • 胸腔镜/机器人手术中转开胸风险较高,术前应告知肺门炎症纤维化可能。

局限性

  • I期小样本探索性研究,结果需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We conducted a phase I trial of neoadjuvant nivolumab, a monoclonal antibody to the programmed cell death protein 1 checkpoint receptor, in patients with resectable non-small cell lung cancer. We analyzed perioperative outcomes to assess the safety of this strategy. METHODS: Patients with untreated stage I-IIIA non-small cell lung cancer underwent neoadjuvant therapy with 2 cycles of nivolumab (3 mg/kg), 4 and 2 weeks before resection. Patients underwent invasive mediastinal staging as indicated and post-treatment computed tomography. Primary study end points were safety and feasibility of neoadjuvant nivolumab followed by pulmonary resection. Data on additional surgical details were collected through chart review. RESULTS: Of 22 patients enrolled, 20 underwent resection. One was unresectable; another had small cell histologic subtype. There were no delays to surgical resection. Median time from first treatment to surgery was 33 (range, 17-43) days. There were 15 lobectomies, 2 pneumonectomies, 1 bilobectomy, 1 sleeve lobectomy, and 1 wedge resection. Of 13 procedures attempted via a video-assisted thoracoscopic surgery or robotic approach, 7 (54%) required thoracotomy. Median operative time was 228 (range, 132-312) minutes; estimated blood loss was 100 (range, 25-1000) mL; length of hospital stay was 4 (range, 2-17) days. There was no operative mortality. Morbidity occurred in 10 of 20 patients (50%). The most common postoperative complication was atrial arrhythmia (6/20; 30%). Major pathologic response was identified in 9 of 20 patients (45%). CONCLUSIONS: Neoadjuvant therapy with nivolumab was not associated with unexpected perioperative morbidity or mortality. More than half of the video-assisted thoracoscopic surgery/robotic cases were converted to thoracotomy, often because of hilar inflammation and fibrosis.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Bott MJ, Yang SC, Park BJ, et al. Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2018. PMID: 30718052. doi:10.1016/j.jtcvs.2018.11.124

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。